Back to top

oncology-screening: Archive

Zacks Equity Research

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.

AZNPositive Net Change MRKPositive Net Change IMTXNegative Net Change TRDANegative Net Change

Zacks Equity Research

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.

ABBVPositive Net Change IMTXNegative Net Change TRDANegative Net Change

Kevin Cook

Bull of the Day: NVIDIA (NVDA)

After Computex, I raised my price target to $200 because Wall Street still has no idea what's coming

NVDAPositive Net Change